Day 1 – Wednesday, 11th September - EST/EDT (Eastern Daylight, GMT-4)
Day 1 – Wednesday, 11th September - EST/EDT (Eastern Daylight, GMT-4)
- Caitlin McNally - Conference Director- Medtech Lead, LSX
- Joseph Smith - CSO, BD
- Carla Peron - Chief Medical Officer, Philips
- Trang Ly - SVP Medical Director, Insulet Corporation
Throughout 2023, considerable discourse unfolded regarding the prospective role of AI in the healthcare sector and its capacity to redefine healthcare delivery. From advancements in robotics, navigation, augmented reality, to the integration of remote sensors, digital technologies have demonstrated their capability to enhance clinical, operational, and financial outcomes. While this transformation has been evident in theoretical discussions and the emergence of pioneering medtech startups incorporating AI, a critical question persists: has the actual implementation and maturity of these technologies resulted in a sustained and disruptive impact on the healthcare industry?
- In what ways has AI propelled advancements in medtech
- What obstacles have been encountered during the implementation process
- Has the value and impact of the benefits justified the initial hype and rapid influx of funding
- Susan Wood - CEO, Vida Diagnostics
- Karen Holzberger - President & CEO, SpinTech MRI
- Carlos Morales - VP Research & Development, DYSIS
In the midst of challenging macroeconomic conditions, medtech firms pursuing later-stage funding need to showcase robust revenue projections and tangible growth to entice investors who prioritize companies with unique revenue models. A panel of seasoned investors will delve into the strategies employed by companies, discussing innovative financial structures with strategic partners and the utilization of venture debt as a catalyst for driving sustained growth.
- What trends or strategies do investors prioritize when assessing a medtech company's revenue outlook
- How do successful medtech firms attract later-stage funding amid challenging economic conditions
- Key considerations for medtech firms utilizing venture debt as a catalyst for sustained growth
- David Kereiakes - Managing Partner, Windham Venture Partners
- Michael Sherman - Venture Partner, RA Capital Management
- Darshana Zaveri - Managing Partner, Catalyst Health Ventures
The US medtech industry stands as a global leader, attracting both domestic and international companies. However, navigating the intricate regulatory landscape in the US, especially with recent changes in digital health and AI documentation, poses a formidable challenge. A panel of industry regulatory experts gathers to discuss essential strategies for building a robust regulatory foundation.
- Understanding FDA requirements and relationship building
- Building clinical evidence and exploring expedited pathways
- Developing a robust pre-submission strategy
- Karen Cross - Co-Founder & CEO, MIMOSA Diagnostics
- John Konsin - CEO & Co-Founder, Prapela
- Christy Sheehy-Bensinger - CEO & Founder, C-Light Technologies
- Cathy Skinner - CEO, NXgenPort Inc
- Kevin Stevens - Head, Global Regulatory Affairs Device, PDT, Takeda
- Blake Richards - CEO, Elucid
The competitive medtech landscape requires organizations to not only secure 510(k) FDA clearance but also effectively communicate the clinical and economic value of their technology in the evolving landscape of value-based care. Essential strategies for success encompass showcasing value to diverse stakeholders and developing comprehensive market access plans. A panel of senior leaders in the world of market access, discuss what medtech companies need to know once they’ve achieved clearance or approval.
- Navigating post-market surveillance and evidence generation
- Establishing an entity in the U.S
- Reimbursement pathways and finding distributors
- Christine Horton - CEO, Visura Technologies
- Nishant Doctor - CEO, Surf Therapeutics
- Marc Jones - CEO, Altoida
In the dynamic healthcare sector, market challenges and disruptions affect both new and established players. This panel explores how industry-wide collaboration, offering disruptive solutions, can address market challenges, enhance resilience, and drive long-term growth.
- Leveraging partnerships and collaborations within the industry
- Utilising AI and how to partner with providers of data
- Working with healthcare providers to create ‘beyond the product’ solutions
- Implications of out-sourcing needs
- Debbie Lin - Venture Partner, T.Rx Capital
- Kurt Haggstrom - CCO, Synchron
- Ana Maiques - CEO & Co-Founder, Neuroelectrics
- Jonathan Hoyt - Executive Director, Global Market Development, Olympus Corporation of the Americas
Medtech startups face challenges in fundraising due to a shortage of early-stage investors and obstacles on the path to commercialization. Despite substantial growth in venture funding for the medtech sector, there's a noticeable shift towards mid to later-stage investments, driven by reduced returns and complexities in reimbursement. Investors now prioritize ventures that combine security, innovation, and clinical success. Learn from early-stage investors about their evaluation criteria and discover effective strategies to cultivate relationships, improving the chances of securing seed or series A funding. This session explores how early-stage medtech firms can navigate the journey from initial funding to market success, aligning with investors' evolving expectations.
- Aligning with investor expectations
- Bridging the funding to viability gap
- Building investor-attractive foundations
- Creating a strong investment proposition
- Gwen Watanabe - Managing Director, H.I.G. Capital
- Amy Salzhauer - Founder & Managing Partner, Good Growth Capital
- Tom Miller - Founding & Managing Partner, GreyBird Ventures, LLC